| AbbVie is a research-based biopharmaceutical company. Co.'s portfolio of products includes a line of therapies that addresses serious diseases such as: HUMIRA (adalimumab) to treat autoimmune diseases; oncology products such as IMBRUVICA (ibrutinib) and Venclexta (venetoclax); virology products such as VIEKIRA PAK for the treatment of hepatitis C and Norvir (ritonavir) for the treatment of human immunodeficiency virus-1 infection; metabolic and hormone products that target conditions such as testosterone deficiency; endocrinology products such as Lupron (leuprolide acetate) for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty. We show 24 historical shares outstanding datapoints in our ABBV shares outstanding history coverage, used to compute ABBV market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ABBV market cap history over the course of time is important for investors
interested in comparing ABBV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ABBV versus a peer is one thing; comparing
ABBV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ABBV can fluctuate over the course of history.
With this page we aim to empower investors researching ABBV by allowing them to research the ABBV market cap history.